by Marco Torres
October 25, 2013
from
NaturalBlaze Website
A man with excruciating pains following multiple traumas was
monitored, daily, over one year while managing chronic pain by
self-administering quantifiable amounts of natural cannabis.
Tetrahydro-cannabinol, Cannabidiol, and
Cannabinol were all measured in tinctures, capsules, smoke-able
product plus some baked goods, prior to their administration. By
allowing standardization, the man was able to develop a daily
regimen of pain management that was resistant to a battery of most
patented analgesics.
More than 100 million people in the United States suffer from
debilitating chronic pain. Pain resulting from a severe on-the-job
injury is a frustrating experience both for the patient as well as
the treating health practitioners and physicians.
If pursuing conventional medical care,
it leads to chronic dependence on opiate painkillers and
anti-depressants which eventually cause toxicity of the brain and
metabolic function. However the relief of pain may be less desired
if quality of life of such individuals is poor.
The physician and the patients are left
with no option but to resort to alternative modes of therapy.
Some studies have
examined the effect of adding a cannabinoid to the regimen of
patients with chronic pain who report significant pain despite
taking stable doses of potent opioids.
An
investigational cannabinoid therapy helped provide effective
analgesia when used as an adjuvant medication for cancer
patients with pain that responded poorly to opioids, according
to results of a multicenter trial reported in
The Journal of Pain,
published by the American Pain Society.
When patients begin to consume cannabis, there is a notable
decline in the amount of prescribed medications taken, such as
antipsychotics, mood stabilizers, and pain relievers. These
drugs have severe side effects. There is not one clinical study
which examined the use of cannabis for pain relief where
subjects were not able to reduce their drug intake.
A
U.S. Patent 6630507 was initiated in 2003 when researchers
found that cannabinoids, high ratios which are found in
marijuana, had specific antioxidant properties making them
useful in the treatment and prophylaxis of wide variety of
oxidation associated diseases, such as ischemic, age-related,
inflammatory and autoimmune diseases. The cannabinoids are found
to have particular application as neuroprotectants, for example
in limiting neurological damage following ischemic insults, such
as stroke and trauma, or in the treatment of neurodegenerative
diseases, such as Alzheimer's disease, Parkinson's disease and
HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil,
are particularly advantageous to use because they avoid toxicity
that is encountered with psychoactive cannabinoids at high doses
useful in the method of the present invention.
Study Details
The person involved in this study was a member of the Green
Cross Society of British Columbia, which has Federal tax number
to distribute cannabis for medical purposes. The Society
provides natural product (cannabis, herbal medicine) to its
qualified members.
The volunteer, a 33 year old Caucasian male, volunteer was
selected from the membership based on his record keeping
ability, the severity of his injury, plus his daily presence at
the Society, allowing continuous monitoring. The man kept
detailed notes of his condition, including pain charts,
medications and dietary habits, allowing comparison by study
observers. The individuals note taking allowed an in depth
review of his condition. The case described here is strikingly
similar to four others of its type, run over the same year, with
comparable observations and outcome.
The cannabis supplied by the Societys contracted growers was
optimized for THC concentration through genetic selection of
specific strains, growing conditions and fertilizers. Organic
growing conditions were a priority.
For 15 months the man was monitored for all forms of cannabis
use. They accumulated data on the amount of smoke-able,
encapsulated, edible and tincture preparations consumed by the
man on a daily basis. His prescription record, physicians notes,
urine (drug) tests, plus daily interviews were maintained and
examined. Daily cannabis use totaling 10 g of natural product
cannabis, translating to an average of 420-500 mg of THC, 40-80
mg of CBD and 20-60 mg CBN, was required to achieve a sufficient
degree of pain management.
Significant reductions in daily pain scores as well as improved
sleep, muscle spasm and general quality of life were achieved.
The patient was able to get back to the daily activities, do
some part time volunteer work, go to the gym, and lead what
resembles a normal life.
He consumed 10-15 g of cannabis per day. He also found benefit
in a number of supplements: for chronic pain and depression,
including,
GABA(500 mg),
L- Tyrosine (500 mg), L-Tryptophan (550 mg),
DL- Phenylalanine (500 mg) and
S-adenosyl methionine (liquid) 40 drops a day. For the
breakthrough pain he used cannabis tincture at 10 mg THC/drop; 2
mg CBD/drop: 15-25 drops (as needed), which relieved intense
pain, in a couple of seconds. He also used Volcano (vaporizer),
2-4 g a day. A medical examination showed all liver functions to
be normal, including clearance of the hypercholesterolemia.
There Is No Longer Doubt That Cannabis Addressed Pain Relief
The analgesic properties of cannabis are becoming well
established in the literature. The purpose of this case study
was to observe the efficacy and usefulness of the standardized
whole plant cannabis
medicine. Indeed, the complexities of elucidating the efficacy
of such preparations is a difficult task, yet the benefits of
the natural product far outweigh the contrary in consideration
of toxicity, efficacy and side-effects. With regard to the
latter, more frequently unwanted side effects from cannabis
result from overdose than any other parameter. And, most
frequently, this overdose results from oral ingestion of
un-standardized baked goods (i.e. brownies).
Overdose results in confusion, paranoia and fear that subsides
after four to six hours, often into sleep. In no case, has it
been observed to cause permanent physical or mental damage, but
can often leave the individual with extreme caution to repeating
the event. The second most frequently observed un-wanted side
effects arise from incorrect strain selection for the symptom.
For example, a person seeking pain relief and also suffering
from anxiety, chooses a strain containing high concentrations of
CBN, with little comparative CBD and low THC, may experience
increased anxiety, with little or no pain relief. Another
important observation is that there is a genealogical factor in
tolerance experienced by individuals of different ethnic
backgrounds. Persons of Celtic descent (Scottish, Irish or
Welsh) appear to be 3 to 5 times more tolerant to cannabis than
persons of middle European or African descent. The person
described in this study had a Scottish mother, which may explain
the high THC levels required by him, but not by persons in
similar studies but of different ethnic background.
Proven Results With Cannabis
With 70% of the members treating chronic pain the same
phenomenon is observed over and over that people achieve a
significant degree of pain management using standardized natural
product cannabis. Often a better quality of life is attained
with cannabis use only. The subject in this study was nearly one
year using only natural product cannabis plus supplements for
his severe pain. He then went through yet another two surgeries
to back and hand using only cannabis for postoperative pain.
Source:
casesjournal.com
sciencedaily.com
jpain.org - See more at: http://www.naturalblaze.com/2013/10/man-heals-his-excruciating-pain-with.html#sthash.DgEXNBBZ.dpuf
Some studies (Efficacy
of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on
Opioid Therapy) have examined the effect of adding a cannabinoid to the regimen of patients with chronic pain who report significant pain despite taking stable doses of potent opioids.
An
investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial reported in
The Journal of Pain, published by the American Pain Society.
When patients begin to consume cannabis, there is a notable decline in the amount of prescribed medications taken, such as antipsychotics, mood stabilizers, and pain relievers. These drugs have severe side effects.
There is not one clinical study which examined the use of cannabis for pain relief where subjects were not able to reduce their drug intake.
A
U.S. Patent 6630507 was initiated in 2003 when researchers found that cannabinoids, high ratios which are found in marijuana, had specific antioxidant properties making them useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.
The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia.
Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.
Study Details
The person involved in this study was a member of the Green Cross Society of British Columbia, which has Federal tax number to distribute cannabis for medical purposes.
The Society provides natural product (cannabis, herbal medicine) to its qualified members.
The volunteer, a 33 year old Caucasian male, volunteer was selected from the membership based on his record keeping ability, the severity of his injury, plus his daily presence at the Society, allowing continuous monitoring. The man kept detailed notes of his condition, including pain charts, medications and dietary habits, allowing comparison by study observers.
The individuals note taking allowed an in depth review of his condition. The case described here is strikingly similar to four others of its type, run over the same year, with comparable observations and outcome.
The cannabis supplied by the Society contracted growers was optimized for THC concentration through genetic selection of specific strains, growing conditions and fertilizers. Organic growing conditions were a priority.
For 15 months the man was monitored for all forms of cannabis use.
They accumulated data on the amount of smoke-able, encapsulated, edible and tincture preparations consumed by the man on a daily basis. His prescription record, physicians notes, urine (drug) tests, plus daily interviews were maintained and examined.
Daily cannabis use totaling 10 g of natural product cannabis, translating to an average of 420-500 mg of THC, 40-80 mg of CBD and 20-60 mg CBN, was required to achieve a sufficient degree of pain management.
Significant reductions in daily pain scores as well as improved sleep, muscle spasm and general quality of life were achieved. The patient was able to get back to the daily activities, do some part time volunteer work, go to the gym, and lead what resembles a normal life.
He consumed 10-15 g of cannabis per day.
He also found benefit in a number of supplements: for chronic pain and depression, including,
For the breakthrough pain he used,
-
cannabis tincture at 10 mg THC/drop
-
2 mg CBD/drop: 15-25 drops (as needed), which relieved intense pain, in a couple of seconds
-
he also used
Volcano (vaporizer), 2-4 g a day
A medical examination showed all liver functions to be normal, including clearance of the hypercholesterolemia.
There Is No Longer Doubt That Cannabis Addressed Pain Relief
The analgesic properties of cannabis are becoming well established in the literature.
The purpose of this case study was to observe the efficacy and usefulness of the standardized whole plant cannabis
medicine. Indeed, the complexities of elucidating the efficacy of such preparations is a difficult task, yet the benefits of the natural product far outweigh the contrary in consideration of toxicity, efficacy and side-effects.
With regard to the latter, more frequently unwanted side effects from cannabis result from overdose than any other parameter. And, most frequently, this overdose results from oral ingestion of un-standardized baked goods (i.e. brownies).
Overdose results in confusion, paranoia and fear that subsides after four to six hours, often into sleep.
In no case, has it been observed to cause permanent physical or mental damage, but can often leave the individual with extreme caution to repeating the event. The second most frequently observed un-wanted side effects arise from incorrect strain selection for the symptom.
For example, a person seeking pain relief and also suffering from anxiety, chooses a strain containing high concentrations of CBN, with little comparative CBD and low THC, may experience increased anxiety, with little or no pain relief.
Another important observation is that there is a genealogical factor in tolerance experienced by individuals of different ethnic backgrounds. Persons of Celtic descent (Scottish, Irish or Welsh) appear to be 3 to 5 times more tolerant to cannabis than persons of middle European or African descent.
The person described in this study had a Scottish mother, which may explain the high THC levels required by him, but not by persons in similar studies but of different ethnic background.
Proven Results With Cannabis
With 70% of the members treating chronic pain, the same phenomenon is observed over and over that people achieve a significant degree of pain management using standardized natural product cannabis.
Often a better quality of life is attained with cannabis use only. The subject in this study was nearly one year using only natural product cannabis plus supplements for his severe pain.
He then went through yet another two surgeries to back and hand using only cannabis for postoperative pain.
Sources
|